Volume 32, Issue 12 (March 2022)
Studies in Medical Sciences 2022, 32(12): 953-962 |
Back to browse issues page
Ethics code: I.R.UMSU.REC.1398.257
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Houshmand H, Farhadi R, Ghaemi M R, Rasouli J. Evaluation of the Neutrophil to Lymphocyte Ratio in the Patients of Kawasaki Disease Resistant to Intravenous immunoglobulin (IVIg) Therapy. Studies in Medical Sciences 2022; 32 (12) :953-962
URL: http://umj.umsu.ac.ir/article-1-5728-en.html
URL: http://umj.umsu.ac.ir/article-1-5728-en.html
Assistant Professor of Epidemiology, Department of Biostatistics and Epidemiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran (Corresponding Author) , rsljvd@yahoo.com
Abstract: (1505 Views)
Background & Aims: Kawasaki disease is a systemic vasculitis of unknown etiology that is common in the pediatric patients. The primary therapeutic strategy includes aspirin and Intravenous Immunoglobulin. The present study aimed to investigate the Neutrophil to Lymphocyte Ratio (NLR) in the patients with Kawasaki and its relationship with the resistance to IVIg therapy.
Materials and Methods: The present study included the patients presenting to the Motahari Hospital, Urmia, Iran, whom diagnosed with Kawasaki disease and received IVIg during 2008-2019. The authors collected the data from the patients' medical records and re-assessed the patients' data for meeting the diagnostic criteria for Kawasaki. Afterward, the data of eligible patients entered the analysis.
Results: The data from 460 patients were obtained and assessed for meeting the diagnostic criteria for Kawasaki. Of 460 patients, 241 met the eligibility criteria, and the data for other patients that meet exclusion criteria were excluded from the study. According to the results of our study, response to IVIg therapy had a significant relationship with the variables of blood and urinary leukocyte counts (p=0.013 and p=0.01, respectively). However, we didn’t find any significant relationship between the response to IVIg therapy and the variables of age, gender, NLR, neutrophil count, lymphocyte count, C-Reactive Protein (CRP), serum albumin level, ALT, hemoglobin, platelet count, and the interval between onset of symptoms and treatment initiation.
Conclusion: High blood leukocyte count along with low urinary leukocyte count can predict the response to IVIg treatment and subsequent prognosis in the patients affected by the Kawasaki disease. However, the NLR did not show clinical relevance.
Materials and Methods: The present study included the patients presenting to the Motahari Hospital, Urmia, Iran, whom diagnosed with Kawasaki disease and received IVIg during 2008-2019. The authors collected the data from the patients' medical records and re-assessed the patients' data for meeting the diagnostic criteria for Kawasaki. Afterward, the data of eligible patients entered the analysis.
Results: The data from 460 patients were obtained and assessed for meeting the diagnostic criteria for Kawasaki. Of 460 patients, 241 met the eligibility criteria, and the data for other patients that meet exclusion criteria were excluded from the study. According to the results of our study, response to IVIg therapy had a significant relationship with the variables of blood and urinary leukocyte counts (p=0.013 and p=0.01, respectively). However, we didn’t find any significant relationship between the response to IVIg therapy and the variables of age, gender, NLR, neutrophil count, lymphocyte count, C-Reactive Protein (CRP), serum albumin level, ALT, hemoglobin, platelet count, and the interval between onset of symptoms and treatment initiation.
Conclusion: High blood leukocyte count along with low urinary leukocyte count can predict the response to IVIg treatment and subsequent prognosis in the patients affected by the Kawasaki disease. However, the NLR did not show clinical relevance.
Type of Study: Research |
Subject:
آسم و آلرژی کودکان
References
1. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364(9433):533-44. [DOI:10.1016/S0140-6736(04)16814-1]
2. Narayanan SN, Ahamed MZ, Safia M. Cardiovascular involvement in Kawasaki disease. Indian Pediatr. 2005;42(9):918-22. [Google Scholar]
3. Ng YM, Sung RY, So LY, Fong NC, Ho MH, Cheng YW, et al. Kawasaki disease in Hong Kong, 1994 to 2000. Hong Kong Med J 2005;11(5):331-5. [Google Scholar]
4. Krohn C, Till H, Haraida S, Kurnik K, Boehm R, Grantzow R, et al. Multiple intestinal stenoses and peripheral gangrene: a combination of two rare surgical complications in a child with Kawasaki disease. J Pediatr Surg 2001;36(4):651-3. [DOI:10.1053/jpsu.2001.22312] [PMID]
5. Baker AL, Lu M, Minich LL, Atz AM, Klein GL, Korsin R, et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr 2009;154(4):592-5. [DOI:10.1016/j.jpeds.2008.10.006] [PMID] [PMCID]
6. Burns JC, Mason WH, Glode MP, Shulman ST, Melish ME, Meissner C, et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr 1991;118(5):680-6. [DOI:10.1016/S0022-3476(05)80026-5]
7. Cai Z, Zuo R, Liu Y. Characteristics of Kawasaki disease in older children. Clin Pediatr 2011;50(10):952-6. [DOI:10.1177/0009922811409027] [PMID]
8. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017;135(17):e927-e99. [DOI:10.1161/CIR.0000000000000484] [PMID]
9. Kawamura Y, Takeshita S, Kanai T, Yoshida Y, Nonoyama S. The Combined Usefulness of the Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Predicting Intravenous Immunoglobulin Resistance with Kawasaki Disease. J Pediatr 2016;178:281-4. [DOI:10.1016/j.jpeds.2016.07.035] [PMID]
10. Ha KS, Lee J, Jang GY, Lee J, Lee KC, Son CS, et al. Value of neutrophil-lymphocyte ratio in predicting outcomes in Kawasaki disease. Am J Cardiol 2015;116(2):301-6. [DOI:10.1016/j.amjcard.2015.04.021] [PMID]
11. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102(1):5-14. [Google Scholar]
12. Kliegman RM. Nelson textbook of pediatrics. 21st edition. ed. Philadelphia, MO: Elsevier;2019. [URL]
13. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149(2):237-40. [DOI:10.1016/j.jpeds.2006.03.050] [PMID]
14. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113(22):2606-12. [DOI:10.1161/CIRCULATIONAHA.105.592865] [PMID]
15. Cho HJ, Bak SY, Kim SY, Yoo R, Baek HS, Yang S, et al. High neutrophil: lymphocyte ratio is associated with refractory Kawasaki disease. Pediatr Int 2017;59(6):669-74. [DOI:10.1111/ped.13240] [PMID]
16. Lee SM, Lee JB, Go YB, Song HY, Lee BJ, Kwak JH. Prediction of resistance to standard intravenous immunoglobulin therapy in kawasaki disease. Korean Circ J 2014;44(6):415-22. [DOI:10.4070/kcj.2014.44.6.415] [PMID] [PMCID]
17. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111(12):1805-12. [DOI:10.1172/JCI200318921]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
